



Universiteit
Leiden
The Netherlands

Innate immunity in osteosarcoma

Buddingh, E.P.

Citation

Buddingh, E. P. (2014, March 5). *Innate immunity in osteosarcoma*. Retrieved from <https://hdl.handle.net/1887/24366>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/24366>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/24366> holds various files of this Leiden University dissertation

Author: Buddingh, Emilie Pauline

Title: Innate immunity in osteosarcoma

Issue Date: 2014-03-05



Addendum



REFERENCES

1. **European and American Osteosarcoma Study Group.** <http://www.ctu.mrc.ac.uk/euramos/>
2. WHO Classification of Tumours of Soft Tissue and Bone. Lyon: International Agency for Research on Cancer, 2013.
3. Addison CL, Daniel TO, Burdick MD, Liu H, Ehler JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. *J Immunol* 2000;165:5269-5277.
4. Aksnes LH, Hall KS, Folleraas G, Stenwig AE, Bjerkehagen B, Taksdal I, Winderen M, Bruland OS, Saeter G. Management of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience. *Acta Oncologica* 2006;45:38-46.
5. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. *Clin Exp Immunol* 2012;167:195-205.
6. Ancuta P, Liu KY, Misra V, Wacleche VS, Gosselin A, Zhou XB, Gabuzda D. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+and CD16-monocyte subsets. *Bmc Genomics* 2009;10.
7. Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL. Interferon-alpha in acute myeloid leukemia: an old drug revisited. *Leukemia* 2011;25:739-748.
8. AnningaJK, GelderblomH, FioccoM, KroepJR, TaminiauAH, HogendoornPCW, EgelerRM. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? *Eur J Cancer* 2011;47:2431-2445.
9. Aoki N, Kimura Y, Kimura S, Nagato T, Azumi M, Kobayashi H, Sato K, Tateno M. Expression and functional role of MDL-1 (CLECSA) in mouse myeloid lineage cells. *Journal of Leukocyte Biology* 2009;85:508-517.
10. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Noguees C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. *Nature Medicine* 2007;13:1050-1059.
11. Athanasou NA, Quinn J. Immunophenotypic Differences Between Osteoclasts and Macrophage Polykaryons - Immunohistological Distinction and Implications for Osteoclast Ontogeny and Function. *Journal of Clinical Pathology* 1990;43:997-1003.
12. Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Faggioli F, Versari M, Picci P. Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. *Acta Oncologica* 2005;44:748-755.
13. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy - 15-year experience in 789 patients treated at a single institution. *Cancer* 2006;106:1154-1161.
14. Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, Forni C, Briccoli A. High Grade Osteosarcoma of the Extremities With Lung Metastases at Presentation: Treatment With Neoadjuvant Chemotherapy and Simultaneous Resection of Primary and Metastatic Lesions. *Journal of Surgical Oncology* 2008;98:415-420.
15. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE. Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. *Blood* 2007;110:2764-2767.
16. Bauer S, Pigisch S, Hangel D, Kaufmann A, Hamm S. Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9. *Immunobiology* 2008;213:315-328.
17. Begum NA, Tsuji S, Nomura R, Shida K, Azuma I, Hayashi A, Matsumoto M, Seya T, Toyoshima K. Human MD-1 homologue is a BCG-regulated gene product in monocytes: Its identification by differential display. *Biochemical and Biophysical Research Communications* 1999;256:325-329.
18. Ben-David U, Mayshar Y, Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. *Cell Stem Cell* 2011;9:97-102.
19. Berger M, Muraro M, Faggioli F, Ferrari S. Osteosarcoma Derived from Donor Stem Cells Carrying the Norrie's Disease Gene. *New England Journal of Medicine* 2008;359:2502-2504.
20. Berghuis D, de Hooge ASK, Santos SJ, Horst D, Wertz EJ, van Eggermond MC, van den Elsen PJ, Taminiau AHM, Ottaviano L, Schaefer KL, Dirksen U, Hooijberg E, Mulder A, Melief CJM, Egeler RM, Schilham MW,

1

2

3

4

5

6

7

8

&

References

- Jordanova ES, Hogendoorn PCW, Lankester AC. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. *J Pathol* 2009;218:222-231.
21. Bernardo ME, Emons JAM, Karperien M, Nauta AJ, Willemze R, Roelofs H, Romeo S, Marchini A, Rappold GA, Vukicevic S, Locatelli F, Fibbe WE. Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. *Connective Tissue Research* 2007;48:132-140.
 22. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. *Cancer Research* 2007;67:9142-9149.
 23. Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, Kevric M, Jundt G, Kuhne T, Maas R, Schwarz R, Zoubek A, Jurgens H. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. *J Clin Oncol* 2009;27:557-565.
 24. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. *J Clin Oncol* 2002;20:776-790.
 25. Bielack SS, Smeland S, Whelan J, Marina N, Hook J, Jovic G, Kramer MD, Butterfass-Bahloul T, Kuhne T, Eriksson M, Teot L, Gelderblom H, Kager L, Hall KS, Gorlick R, Randall RL, Hogendoorn PCW, Calaminus G, Sydes MR, Bernstein ML. MAP plus maintenance pegylated interferon α -2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response" randomization. *J Clin Oncol (Meeting Abstracts)* 2013;31:suppl; abstr LBA10504.
 26. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A. Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. *J Exp Med* 2003;198:557-567.
 27. Boudny V, Dusek L, Adamkova L, Chumchalova J, Kocak I, Fait V, Lauerova L, Krejci E, Kovarik J. Lack of STAT 1 phosphorylation at TYR 701 by IFN γ correlates with disease outcome in melanoma patients. *Neoplasma* 2005;52:330-337.
 28. Bowdish DM, Gordon S. Conserved domains of the class A scavenger receptors: evolution and function. *Immunol Rev* 2009;227:19-31.
 29. Briccoli A, Rocca M, Salone M, Bacci G, Ferrari S, Balladelli A, Mercuri M. Resection of recurrent pulmonary metastases in patients with osteosarcoma. *Cancer* 2005;104:1721-1725.
 30. Bridge JA, Nelson M, McComb E, McGuire MH, Rosenthal H, Vergara G, Maale GE, Spanier S, Neff JR. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. *Cancer Genet Cytogenet* 1997;95:74-87.
 31. Brosjo O, Bauer HC, Brostrom LA, Nilsson U, Nilsson OS, Reinholdt FP, Strander H, Tribukait B. Influence of human alpha-interferon on four human osteosarcoma xenografts in nude mice. *Cancer Res* 1985;45:5598-5602.
 32. Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, Hogendoorn PCW, Lankester AC, Gelderblom H. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. *Pediatr Blood Cancer* 2010;54:216-221.
 33. Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PCW, Lankester AC, Cleton-Jansen AM. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. *Clin Cancer Res* 2011;17:2110-2119.
 34. Buddingh EP, Schilham MW, Ruslan SE, Berghuis D, Szuhai K, Suurmond J, Taminiau AH, Gelderblom H, Egeler RM, Serra M, Hogendoorn PCW, Lankester AC. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. *Cancer Immunol Immunother* 2011;60:575-586.
 35. Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmievich AL. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. *Journal of Immunology* 2006;176:309-318.
 36. Bystrom J, Tenno T, Hakansson L, Amin K, Trulson A, Hogbom E, Venge P. Monocytes, but not macrophages, produce the eosinophil cationic protein. *Apmis* 2001;109:507-516.
 37. Carim-Todd L, Escarceller M, Estivill X, Sumoy L. Cloning of the novel gene TM6SF1 reveals conservation of clusters of paralogous genes between human chromosomes 15q24 -> q26 and 19p13.3 -> p12. *Cytogenetics and Cell Genetics* 2000;90:255-260.

38. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. *Cancer Immunol Immunother* 2007;56:227-236.
39. Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, Lei HY, Lee CK, Chiou TW, Wong CH, Hsieh SL. CLECSA is critical for dengue-virus-induced lethal disease. *Nature* 2008;453:672-U12.
40. Chiang KP, Niessen S, Saghatelian A, Cravatt BF. An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. *Chemistry & Biology* 2006;13:1041-1050.
41. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. *Clin Cancer Res* 2010;16:3901-3909.
42. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG, Meyers PA. Treatment of osteosarcoma at first recurrence after contemporary therapy - The Memorial Sloan-Kettering Cancer Center Experience. *Cancer* 2005;104:2214-2221.
43. Chowdhry M, Hughes C, Grimer RJ, Sumathi V, Wilson S, Jeys L. Bone sarcomas arising in patients with neurofibromatosis type 1. *J Bone Joint Surg Br* 2009;91:1223-1226.
44. Chowdhury D, Lieberman J. Death by a thousand cuts: Granzyme pathways of programmed cell death. *Annu Rev Immunol* 2008;26:389-420.
45. Chung S, Furihata M, Tamura K, Uemura M, Daigo Y, Nasu Y, Miki T, Shuin T, Fujioka T, Nakamura Y, Nakagawa H. Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. *Oncogene* 2009;28:2849-2859.
46. Cipriani P, Carubbi F, Liakouli V, Marrelli A, Perricone C, Perricone R, Alesse E, Giacomelli R. Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. *Autoimmun Rev* 2012.
47. Cleton-Jansen AM, Anninga JK, Briaire-de B, I, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH, Hogendoorn PCW. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumorigenic pathways. *Br J Cancer* 2009;101:2064.
48. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. *Biochim Biophys Acta* 2009;1796:11-18.
49. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. *Clin Orthop Relat Res* 1991;3-11.
50. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. *Cell* 2000;103:481-490.
51. Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, Lee PP. Impaired interferon signaling is a common immune defect in human cancer. *Proceedings of the National Academy of Sciences of the United States of America* 2009;106:9010-9015.
52. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. *PLoS Med* 2007;4:e176.
53. Crompton BD, Goldsby RE, Weinberg VK, Feren R, O'Donnell RJ, Ablin AR. Survival after recurrence of osteosarcoma: A 20-year experience at a single institution. *Pediatric Blood & Cancer* 2006;47:255-259.
54. Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 1994;264:1415-1421.
55. De Gassart A, Camosseto V, Thibodeau J, Ceppi M, Catalan N, Pierre P, Gatti E. MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. *Proceedings of the National Academy of Sciences of the United States of America* 2008;105:3491-3496.
56. de la Fuente R, Bernad A, Garcia-Castro J, Martin MC, Cigudosa JC. Retraction: Spontaneous human adult stem cell transformation. *Cancer Res* 2010;70:6682.
57. Dohi O, Hatori M, Suzuki T, Ono K, Hosaka M, Akahira JI, Miki Y, Nagasaki S, Itoi E, Sasano H. Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. *Cancer Science* 2008;99:518-523.
58. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans RJ, Keating A, Prockop DJ, Horwitz EM. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315-317.
59. Du P, Kibbe WA, Lin SM. nuID: a universal naming scheme of oligonucleotides for Illumina, Affymetrix, and other microarrays. *Biology Direct* 2007;2.

1

2

3

4

5

6

7

8

&

References

60. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. *Bioinformatics* 2008;24:1547-1548.
61. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. A critical function for type I interferons in cancer immunoeediting. *Nat Immunol* 2005;6:722-729.
62. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoeediting. *Nature Reviews Immunology* 2006;6:836-848.
63. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer* 2002;2:161-174.
64. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, Morgan GJ, Cook GP. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. *Cancer Res* 2007;67:8444-8449.
65. Ewing J. Diffuse endothelioma of bone. *Proceedings of the New York Pathological Society* 1921;12:17.
66. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990;61:759-767.
67. Filen JJ, Filen S, Moulder R, Tuomela S, Ahlfors H, West A, Kouvonen P, Kantola S, Bjorkman M, Katajamaa M, Rasool O, Nyman TA, Lahesmaa R. Quantitative Proteomics Reveals GIMAP Family Proteins 1 and 4 to Be Differentially Regulated during Human T Helper Cell Differentiation. *Molecular & Cellular Proteomics* 2009;8:32-44.
68. Fiory F, Formisano P, Perruolo G, Beguinot F. Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. *Am J Physiol Endocrinol Metab* 2009;297:E592-E601.
69. Fischer-Valuck BW, Barrilleaux BL, Phinney DG, Russell KC, Prockop DJ, O'Connor KC. Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency. *Biotechnol Lett* 2010;32:19-27.
70. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. *Nat Rev Immunol* 2010;10:554-567.
71. Fletcher CDM, Unni KK, Mertens F. *World Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone*. Lyon: IARC Press, 2002.
72. Forment JV, Kaidi A, Jackson SP. Chromothripsis and cancer: causes and consequences of chromosome shattering. *Nat Rev Cancer* 2012;12:663-670.
73. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. *Clinical Cancer Research* 2007;13:1472-1479.
74. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. *Nature Immunology* 2009;10:241-247.
75. Frezzato F, Gattazzo C, Martini V, Trimarco V, Teramo A, Carraro S, Cabrelle A, Ave E, Facco M, Zambello R, Tibaldi E, Brunati AM, Semenzato G, Trentin L. HSI1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen. *PLoS ONE* 2012;7:e39902.
76. Frings PW, Van Elssen CH, Wieten L, Matos C, Hupperets PS, Schouten HC, Bos GM, van GM. Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice. *Breast Cancer Res Treat* 2011;130:773-781.
77. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. *Nature* 2005;437:1043-1047.
78. Fujiwara T, Fukushi J, Yamamoto S, Matsumoto Y, Setsu N, Oda Y, Yamada H, Okada S, Watari K, Ono M, Kuwano M, Kamura S, Iida K, Okada Y, Koga M, Iwamoto Y. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. *Am J Pathol* 2011;179:1157-1170.
79. Ganesan LP, Fang HQ, Marsh CB, Tridandapani S. The protein-tyrosine phosphatase SHP-1 associates with the phosphorylated immunoreceptor tyrosine-based activation motif of Fc gamma RIIa to modulate signaling events in myeloid cells. *Journal of Biological Chemistry* 2003;278:35710-35717.
80. Garcia-Iglesias T, del Toro-Arreola A, barran-Somoza B, del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Duenas MG, Balderas-Pena LM, Bravo-Cuellar A, Ortiz-Lazareno PC, neri-Navarro A. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. *BMC Cancer* 2009;9:186.
81. Ge K, Prendergast GC. Bin2, a functionally nonredundant member of the BAR adaptor gene family. *Genomics* 2000;67:210-220.

82. Geddes K, Magalhaes JG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. *Nature Reviews Drug Discovery* 2009;8:465-479.
83. Gelderblom H, Sydes MR, Morgan RC, Hogendoorn PCW, Lewis IJ, Nooij MA, Taminiau AH, Whelan J. Survival after recurrent osteosarcoma: Data from three European Osteosarcoma Intergroup (EOI) randomized controlled. *J Clin Oncol (Meeting Abstracts)* 2008;26:1050S.
84. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* 2004;5:R80.
85. Gomez TS, McCarney SD, Carrizosa E, Labno CM, Comiskey EO, Nolz JC, Zhu PM, Freedman BD, Clark MR, Rowings DJ, Billadeau DD, Burkhardt JK. HSI functions as an essential actin-regulatory adaptor protein at the immune synapse. *Immunity* 2006;24:741-752.
86. Gordon N, Arndt CAS, Hawkins DS, Dohero DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES. Fas expression in lung metastasis from osteosarcoma patients. *J Pediatr Hematol Oncol* 2005;27:611-615.
87. Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. *Clin Cancer Res* 2007;13:4503-4510.
88. Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). *Cancer Epidemiol Biomarkers Prev* 1996;5:239-246.
89. Grimer RJ, Hogendoorn PCW, Vanel D. Tumours of bone: Introduction. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: IARC, 2013; pp. 244-247.
90. Gulati P, Lemercier C, Guc D, Lappin D, Whaley K. Regulation of the synthesis of C1 subcomponents and C1-inhibitor. *Behring Inst Mitt* 1993;196-203.
91. Gutwein P, Schramme A, Sinke N, bdel-Bakky MS, Voss B, Obermuller N, Doberstein K, Koziolok M, Fritzsche F, Johannsen M, Jung K, Schaidler H, Alteuogt P, Ludwig A, Pfeilschifter J, Kristiansen G. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. *European Journal of Cancer* 2009;45:478-489.
92. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR. "Re-educating" tumor-associated macrophages by targeting NF-kappa B. *Journal of Experimental Medicine* 2008;205:1261-1268.
93. Hagemann T, Wilson J, Burke F, Kulbe H, Li NFF, Plueddemann A, Charles K, Gordon S, Balkwill FR. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. *Journal of Immunology* 2006;176:5023-5032.
94. Hallor KH, Staaf J, Bovee JVMG, Hogendoorn PCW, Cleton-Jansen AM, Knuutila S, Savola S, Niini T, Brosjo O, Bauer HCF, von Steyern FV, Jonsson K, Skorpil M, Mandahl N, Mertens F. Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors. *Clinical Cancer Research* 2009;15:2685-2694.
95. Hansen MF, Koufos A, Gallie BL, Phillips RA, Fodstad O, Brogger A, Gedde-Dahl T, Cavenee WK. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. *Proc Natl Acad Sci U S A* 1985;82:6216-6220.
96. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. *J Bone Miner Res* 2006;21 Suppl 2:58-63.
97. Harting MT, Blakely ML, Jaffe N, Cox CS, Hayes-Jordan A, Benjamin RS, Raymond AK, Andrassy RJ, Lally KP. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. *Journal of Pediatric Surgery* 2006;41:194-199.
98. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PCW. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. *European Journal of Cancer* 2002;38:1218-1225.
99. He X, Zhu Z, Johnson C, Stoops J, Eaker AE, Bowen W, DeFrances MC. PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. *Cancer Research* 2008;68:5591-5598.
100. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le BA, Melero I. Direct effects of type I interferons on cells of the immune system. *Clin Cancer Res* 2011;17:2619-2627.

1

2

3

4

5

6

7

8

&

101. Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, Minami T, Hashimoto I, Nakayama T, Sakurai H, Takano Y, Yoshie O, Tsukada K, Saiki I. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. *Cancer Research* 2007;67:4725-4731.
102. Holland AJ, Cleveland DW. Chromoanagenesis and cancer: mechanisms and consequences of localized, complex chromosomal rearrangements. *Nat Med* 2012;18:1630-1638.
103. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. *Nat Rev Immunol* 2006;6:644-658.
104. Honorati MC, Neri S, Cattini L, Facchini A. IL-17 enhances the susceptibility of U-2OS osteosarcoma cells to NK cell lysis. *Clin Exp Immunol* 2003;133:344-349.
105. Horvai A, Unni KK. Premalignant conditions of bone. *Journal of Orthopaedic Science* 2006;11:412-423.
106. Inui M, Kikuchi Y, Aoki N, Endo S, Maeda T, Sugahara-Tobinai A, Fujimura S, Nakamura A, Kumanogoh A, Colonna M, Takai T. Signal adaptor DAP10 associates with MDL-1 and triggers osteoclastogenesis in cooperation with DAP12. *Proceedings of the National Academy of Sciences of the United States of America* 2009;106:4816-4821.
107. Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, Bunnell BA. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. *Cancer Res* 2008;68:4229-4238.
108. Jacquet S, Malaval C, Martinez LO, Sak K, Rolland C, Perez C, Nauze M, Champagne E, Terce F, Gachet C, Perret B, Collet X, Boeynaems JM, Barbaras R. The nucleotide receptor P2Y(13) is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. *Cellular and Molecular Life Sciences* 2005;62:2508-2515.
109. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. *Trends Immunol* 2010;31:212-219.
110. Jan M, Majeti R. Clonal evolution of acute leukemia genomes. *Oncogene* 2013;32:135-140.
111. Jarvinen A, Keinanen TA, Grigorenko NA, Khomutov AR, Uimari A, Vepsalainen J, Narvanen A, Alhonen L, Janne J. Guide molecule-driven stereospecific degradation of alpha-methylpolyamines by polyamine oxidase. *Journal of Biological Chemistry* 2006;281:4589-4595.
112. Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T. Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma. *Journal of Clinical Oncology* 2009;27:3330-3337.
113. Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N, Kim DW, Yoon YS. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. *Circ Res* 2011;108:1340-1347.
114. Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Post operative infection and increased survival in osteosarcoma patients: Are they associated? *Annals of Surgical Oncology* 2007;14:2887-2895.
115. Johannessen M, Moller S, Hansen T, Moens U, Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. *Cellular and Molecular Life Sciences* 2006;63:268-284.
116. Josse C, Schoemans R, Niessen NA, Delgaudine M, Hellin AC, Herens C, Delvenne P, Bours V. Systematic chromosomal aberrations found in murine bone marrow-derived mesenchymal stem cells. *Stem Cells Dev* 2010;19:1167-1173.
117. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. *DNA Cell Biol* 2007;26:1-18.
118. Karre K. Natural killer cell recognition of missing self. *Nat Immunol* 2008;9:477-480.
119. Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics--a bioconductor package for quality assessment of microarray data. *Bioinformatics* 2009;25:415-416.
120. Kayton ML, Huvos AG, Casher J, Abramson SJ, Rosen NS, Wexler LH, Meyers P, LaQuaglia MP. Computed tomographic scan of the chest underestimates the number of metastatic lesions in osteosarcoma. *Journal of Pediatric Surgery* 2006;41:200-204.
121. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, Gobel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). *Journal of Clinical Oncology* 2005;23:559-568.
122. Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, Jeon YK, Lee SH, Im SA, Chung DH, Kim YT, Kim TY, Bang YJ, Sung SW, Kim JH, Heo DS. High tumour islet macrophage infiltration correlates with improved patient survival but not

- with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. *British Journal of Cancer* 2008;98:1118-1124.
123. Kim J, Kang JW, Park JH, Choi Y, Choi KS, Park KD, Baek DH, Seong SK, Min HK, Kim HS. Biological characterization of long-term cultured human mesenchymal stem cells. *Arch Pharm Res* 2009;32:117-126.
 124. Kim JH, Chu FC, Woodward HQ, Huvos A. Radiation induced sarcomas of bone following therapeutic radiation. *Int J Radiat Oncol Biol Phys* 1983;9:107-110.
 125. Klein MJ, Parisien MV, Schneider-Stock R. Osteogenic Tumours. In: Fletcher CDM, Unni KK, Mertens F, editors. *World Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone*. Lyon: IARC Press, 2002; pp. 259-285.
 126. Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, Benjamin R, Fidler IJ. Unique Histological-Changes in Lung Metastases of Osteosarcoma Patients Following Therapy with Liposomal Muramyl Tripeptide (Cgp-19835A Lipid). *Cancer Immunology Immunotherapy* 1992;34:211-220.
 127. Kolk SM, Pasterkamp RJ. MICAL flavoprotein monooxygenases: Structure, function and role in semaphorin signaling. *Semaphorins: Receptor and Intracellular Signaling Mechanisms* 2007;600:38-51.
 128. Konjevic G, Mirjagic MK, Vuletic A, Jovic V, Jurisic V, Babovic N, Spuzic I. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. *Clin Exp Metastasis* 2007;24:1-11.
 129. Kono H, Rock KL. How dying cells alert the immune system to danger. *Nature Reviews Immunology* 2008;8:279-289.
 130. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: The role of the fas pathway in the metastatic process of osteosarcoma. *Mol Cancer Res* 2007;5:991-999.
 131. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. *Nat Rev Cancer* 2012;12:860-875.
 132. Kubista B, Trieb K, Blahovec H, Kotz R, Micksche M. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis. *Anticancer Res* 2002;22:789-792.
 133. Kubo T, Shimose S, Matsuo T, Fujimori J, Arihiro K, Ochi M. Interferon-alpha/beta receptor as a prognostic marker in osteosarcoma. *J Bone Joint Surg Am* 2011;93:519-526.
 134. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO, Obradovich J, Fidel J, Rosenberg M. Adjuvant therapy for osteosarcoma in dogs: Results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. *Clinical Cancer Research* 1995;1:1595-1601.
 135. Lakshminanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Hoglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Karre K, Shibuya A, Carbone E, Colucci F. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. *J Clin Invest* 2009;119:1251-1263.
 136. Lascelles BD, Dernell WS, Correa MT, Lafferty M, Devitt CM, Kuntz CA, Straw RC, Withrow SJ. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. *Ann Surg Oncol* 2005;12:1073-1083.
 137. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet* 2008;371:1579-1586.
 138. Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, West RB, Gilks CB, van de Rijn M. Prognostic significance of macrophage infiltration in leiomyosarcomas. *Clinical Cancer Research* 2008;14:1423-1430.
 139. Lesinski GB, Badgwell B, Zimmerer J, Crespin T, Hu Y, Abood G, Carson WE, III. IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. *J Immunol* 2004;172:7368-7376.
 140. Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE, III. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. *J Natl Cancer Inst* 2004;96:1331-1342.

1

2

3

4

5

6

7

8

&

141. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PCW, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiu AHM. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. *J Natl Cancer Inst* 2007;99:112-128.
142. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. *J Pathol* 2000;192:150-158.
143. Liebau C, Merk H, Schmidt S, Roesel C, Karreman C, Prisack JB, Bojar H, Baltzer AWA. Interleukin-12 and interleukin-18 change ICAM-1 expression, and enhance natural killer cell mediated cytotoxicity of human osteosarcoma cells. *Cytokines Cell Mol Ther* 2002;7:135-142.
144. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. *Cancer Research* 2006;66:11238-11246.
145. Lin SM, Du P, Huber W, Kibbe WA. Model-based variance-stabilizing transformation for Illumina microarray data. *Nucleic Acids Research* 2008;36.
146. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. *Int J Oncol* 2000;17:445-451.
147. Liu H, Shalev I, Manuel J, He W, Leung E, Crookshank J, Liu MF, Diao J, Cattral M, Clark DA, Isenman DE, Gorczynski RM, Grant DR, Zhang L, Phillips MJ, Cybulsky MI, Levy GA. The FGL2-FcγRIIb pathway: a novel mechanism leading to immunosuppression. *Eur J Immunol* 2008;38:3114-3126.
148. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. *Nat Rev Immunol* 2007;7:329-339.
149. Loges NT, Olbrich H, Fenske L, Mussaffi H, Horvath J, Fliegauf M, Kuhl H, Baktai G, Peterffy E, Chodhari R, Chung EMK, Rutman A, O'Callaghan C, Blau H, Tizslavicz L, Voelkel K, Witt M, Zietkiewicz E, Neesen J, Reinhardt R, Mitchison HM, Omran H. DNAI2 Mutations Cause Primary Ciliary Dyskinesia with Defects in the Outer Dynein Arm. *American Journal of Human Genetics* 2008;83:547-558.
150. Loiselle FB, Morgan PE, Alvarez BV, Casey JR. Regulation of the human NBC3 Na⁺/HCO₃⁻ cotransporter by carbonic anhydrase II and PKA. *American Journal of Physiology-Cell Physiology* 2004;286:C1423-C1433.
151. Luksch R, Perotti D, Cefalo G, Passerini CG, Massimino M, Spreafico F, Casanova M, Ferrari A, Terenzi M, Polastri D, Gambirasio F, Podda M, Bozzi F, Ravagnani F, Parmiani G, Bellani FF. Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. *Tumori* 2003;89:263-268.
152. Ma CS, Nichols KE, Tangye SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. *Annual Review of Immunology* 2007;25:337-379.
153. Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK, Lau CC. Expression profiles of osteosarcoma that can predict response to chemotherapy. *Cancer Res* 2005;65:8142-8150.
154. Manara MC, Serra M, Benini S, Picci P, Scotlandi K. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. *Int J Oncol* 2004;24:365-372.
155. Maran A, Shogren KL, Benedikt M, Sarkar G, Turner RT, Yaszemski MJ. 2-methoxyestradiol-induced cell death in osteosarcoma cells is preceded by cell cycle arrest (vol 104, pg 1937, 2008). *Journal of Cellular Biochemistry* 2008;105:1146.
156. Mariani E, Meneghetti A, Tarozzi A, Cattini L, Facchini A. Interleukin-12 induces efficient lysis of natural killer-sensitive and natural killer-resistant human osteosarcoma cells: The synergistic effect of interleukin-2. *Scand J Immunol* 2000;51:618-625.
157. Mariani E, Tarozzi A, Meneghetti A, Cattini L, Facchini A. Human osteosarcoma cell susceptibility to natural killer cell lysis depends on CD54 and increases after TNF alpha incubation. *FEBS Lett* 1997;406:83-88.
158. Mariani E, Tarozzi A, Meneghetti A, Cattini L, Facchini A. TNF-alpha but not IL-1 and IL-6 modifies the susceptibility of human osteosarcoma cells to NK lysis. *Int J Oncol* 1998;13:349-353.
159. Mariani E, Tarozzi A, Meneghetti A, Tadolini M, Facchini A. Lytic activity of IL-2 and IL-12 stimulated NK cells against HOS osteosarcoma cell line. *Boll Soc Ital Biol Sper* 1996;72:21-27.
160. Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR, Butterfass-Bahloul T, Calaminus G, Bernstein M. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. *Cancer Treat Res* 2009;152:339-353.

161. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression. *Journal of Immunology* 2006;177:7303-7311.
162. Matsumura S, Wang BM, Kawashima N, Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti SC, Dustin ML, Demaria S. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. *Journal of Immunology* 2008;181:3099-3107.
163. McDermott DF. Immunotherapy of metastatic renal cell carcinoma. *Cancer* 2009;115:2298-2305.
164. McHale CM, Smith MT. Prenatal origin of chromosomal translocations in acute childhood leukemia: implications and future directions. *Am J Hematol* 2004;75:254-257.
165. Meneghetti A, Mariani E, Santi S, Riccio M, Cattini L, Paoletti S, Facchini A. NK binding capacity and lytic activity depend on the expression of ICAM-1 on target bone tumours. *Int J Oncol* 1999;15:909-914.
166. Meng W, Mushika Y, Ichii T, Takeichi M. Anchorage of Microtubule Minus Ends to Adherens Junctions Regulates Epithelial Cell-Cell Contacts. *Cell* 2008;135:948-959.
167. Meng X, Fan J, Shen Z. Roles of BCCIP in chromosome stability and cytokinesis. *Oncogene* 2007;26:6253-6260.
168. Mey U, Strehl J, Gorschluter M, Ziske C, Glasmacher A, Pralle H, Schmidt-Wolf I. Advances in the treatment of hairy-cell leukaemia. *Lancet Oncol* 2003;4:86-94.
169. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. *J Clin Oncol* 2005;23:2004-2011.
170. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group. *J Clin Oncol* 2008;26:633-638.
171. Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: A promiscuous subfamily of G protein-coupled receptors controlling immune responses. *Cytokine & Growth Factor Reviews* 2006;17:501-519.
172. Miller BJ, Cram P, Lynch CF, Buckwalter JA. Risk Factors for Metastatic Disease at Presentation with Osteosarcoma: An Analysis of the SEER Database. *J Bone Joint Surg Am* 2013;95:e891-e898.
173. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. *Blood* 2007;109:5058-5061.
174. Miller JS, Soignier Y, Panoskaltis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood* 2005;105:3051-3057.
175. Miller TT. Bone tumors and tumorlike conditions: Analysis with conventional radiography. *Radiology* 2008;246:662-674.
176. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, LaFleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, MacDonald TJ, Gorlick R, Stephan DA. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. *Cancer Research* 2005;65:1748-1754.
177. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. *Cancer* 2009;115:1531-1543.
178. Mistry AR, O'Callaghan CA. Regulation of ligands for the activating receptor NKG2D. *Immunology* 2007;121:439-447.
179. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu BJ, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen WJ, Ried T, Shi ST. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. *Stem Cells* 2006;24:1095-1103.
180. Miura Y, Shimazu R, Miyake K, Akashi S, Ogata H, Yamashita Y, Narisawa Y, Kimoto M. RP105 is associated with MD-1 and transmits an activation signal in human B cells. *Blood* 1998;92:2815-2822.
181. Mohseny AB, Hogendoorn PCW. Concise review: mesenchymal tumors: when stem cells go mad. *Stem Cells* 2011;29:397-403.

1
2
3
4
5
6
7
8

&

References

182. Mohseny AB, Hogendoorn PCW, Cleton-Jansen AM. Osteosarcoma models: from cell lines to zebrafish. *Sarcoma* 2012;2012:417271.
183. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PCW. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. *J Pathol* 2009;219:294-305.
184. Moldenhauer G, Henne C, Karhausen J, Moller P. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments. *Immunology* 1999;96:473-484.
185. Moog-Lutz C, Cave-Riant F, Guibal FC, Breau MA, Di Gioia Y, Couraud PO, Cayre YE, Bourdoulous S, Lutz PG. JAML, a novel protein with characteristics of a junctional adhesion molecule, is induced during differentiation of myeloid leukemia cells. *Blood* 2003;102:3371-3378.
186. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytotoxicity. *Annu Rev Immunol* 2001;19:197-223.
187. Moretti S, Procopio A, Boemi M, Catalano A. Neuronal semaphorins regulate a primary immune response. *Current Neurovascular Research* 2006;3:295-305.
188. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol* 2008;8:958-969.
189. Mulcahy H, O'Rourke KP, Adams C, Molloy MG, O'Gara F. LST1 and NCR3 expression in autoimmune inflammation and in response to IFN-gamma, LPS and microbial infection. *Immunogenetics* 2006;57:893-903.
190. Muller CR, Smeland S, Bauer HC, Saeter G, Strander H. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. *Acta Oncol* 2005;44:475-480.
191. Nakashima Y, Deie M, Yanada S, Sharman P, Ochi M. Magnetically labeled human natural killer cells, accumulated in vitro by an external magnetic force, are effective against HOS osteosarcoma cells. *Int J Oncol* 2005;27:965-971.
192. Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, Yagita H, Okumura K. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. *Blood* 2009;113:3821-3830.
193. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccocanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. *Nature Medicine* 2007;13:54-61.
194. Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A, Naka N, Araki N, Kudawara I, Ieguchi M, Toyama Y, Toguchida J, Yoshikawa H, Nakamura Y. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. *Int J Oncol* 2004;24:647-655.
195. Ojalvo LS, King W, Cox D, Pollard JW. High-Density Gene Expression Analysis of Tumor-Associated Macrophages from Mouse Mammary Tumors. *American Journal of Pathology* 2009;174:1048-1064.
196. Okazaki H, Igarashi M, Nishi M, Sekiya M, Tajima M, Takase S, Takanashi M, Ohta K, Tamura Y, Okazaki S, Yahagi N, Ohashi K, memiya-Kudo M, Nakagawa Y, Nagai R, Kadowaki T, Osuga J, Ishibashi S. Identification of Neutral Cholesterol Ester Hydrolase, a Key Enzyme Removing Cholesterol from Macrophages. *Journal of Biological Chemistry* 2008;283:33357-33364.
197. Olety B, Walte M, Honnert U, Schillers H, Bahler M. Myosin 1G (Myo1G) is a haematopoietic specific myosin that localises to the plasma membrane and regulates cell elasticity. *FEBS Lett* 2009.
198. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. *Nature* 2001;410:701-705.
199. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PCW, Buerger H, Aigner T, Gabbert HE, Poremba C. Molecular Characterization of Commonly Used Cell Lines for Bone Tumor Research: A Trans-European EuroBoNet Effort. *Genes Chromosomes Cancer* 2010;49:40-51.
200. Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, Gelderblom H, Hogendoorn PCW, Egeler RM, Schilham MW, Lankester AC. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. *Clin Cancer Res* 2012;18:432-441.
201. Pampalona J, Frias C, Genesca A, Tusell L. Progressive telomere dysfunction causes cytokinesis failure and leads to the accumulation of polyploid cells. *PLoS Genet* 2012;8:e1002679.
202. Pansuriya TC, van ER, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, van WT, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciort R,

- Limaye N, Kindblom LG, Daugaard S, Godfraind C, Boon LM, Vikkula M, Kurek KC, Szuhai K, French PJ, Bovee JV. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. *Nat Genet* 2011;43:1256-1261.
203. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. *Clin Cancer Res* 2011;17:6287-6297.
204. Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, Scotlandi K, Picci P, Serra M. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. *Cancer Res* 2008;68:6661-6668.
205. Petrilli AS, Gentil FC, Epelman S, Lopes LF, Bianchi A, Lopes A, Figueiredo MTD, Marques E, Debellis N, Consentino E, Prospero D, Decamargo OP, Oliveira NR, Franco E, Jaffe N. Increased Survival, Limb Preservation, and Prognostic Factors for Osteosarcoma. *Cancer* 1991;68:733-737.
206. Picci P, Sieberova G, Alberghini M, Ballardelli A, Vanel D, Hogendoorn PCW, Mercuri M. Late sarcoma development after curettage and bone grafting of benign bone tumors. *Eur J Radiol* 2011;77:19-25.
207. Platanius LC. Mechanisms of type-I- and type-II- interferon-mediated signalling. *Nat Rev Immunol* 2005;5:375-386.
208. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. *Nature Reviews Cancer* 2004;4:71-78.
209. Prockop DJ, Keating A. Relearning the lessons of genomic stability of human cells during expansion in culture: implications for clinical research. *Stem Cells* 2012;30:1051-1052.
210. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. *Cell* 2010;141:39-51.
211. R Foundation for Statistical Computing. R: A language and environment for statistical computing, reference index version 2.9.0. 2005. Vienna, Austria. (Computer Program).
212. Rashid S, Pilecka I, Torun A, Olchowik M, Bielinska B, Miaczynska M. Endosomal Adaptor Proteins APPL1 and APPL2 Are Novel Activators of beta-Catenin/TCF-mediated Transcription. *Journal of Biological Chemistry* 2009;284:18115-18128.
213. Raulet DH, Vance RE. Self-tolerance of natural killer cells. *Nature Reviews Immunology* 2006;6:520-531.
214. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, editors. *World Health Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone*. Lyon: IARC Press, 2002; pp. 264-270.
215. Riihonen R, Song I, Nielsen S, Laitala-Leinonen T, Kwon T. Electroneutral sodium/bicarbonate cotransporter NBCn1 is expressed in rat osteoclast ruffled border membrane. *Journal of Bone and Mineral Research* 2007;22:S253.
216. Rissoan MC, Duhon T, Bridon JM, Driss-Vermare N, Peronne C, de Saint Vis B, Briere F, Bates EEM. Subtractive hybridization reveals the expression of immunoglobulinlike transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. *Blood* 2002;100:3295-3303.
217. Rosenberg AE, Cleton-Jansen AM, de Pinieux G, Deyrup AT, Hauben E, Squire J. Conventional osteosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. *WHO Classification of Tumours of Soft Tissue and Bone*. Lyon: IARC, 2013; pp. 282-288.
218. Rosland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwicz J, Tonn JC, Goldbrunner R, Lonning PE, Bjerkvig R, Schichor C. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. *Cancer Res* 2009;69:5331-5339.
219. Ross AL, Leder DE, Weiss J, Izakovic J, Grichnik JM. Genomic instability in cultured stem cells: associated risks and underlying mechanisms. *Regen Med* 2011;6:653-662.
220. Rozeman LB, Hameetman L, Cleton-Jansen AM, Taminiou AHM, Hogendoorn PCW, Bovee JVMG. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. *Journal of Pathology* 2005;205:476-482.
221. Rubio D, Garcia S, De la Cueva T, Paz MF, Lloyd AC, Bernad A, Garcia-Castro J. Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. *Experimental Cell Research* 2008;314:691-698.
222. Rubio D, Garcia S, Paz MF, De la CT, Lopez-Fernandez LA, Lloyd AC, Garcia-Castro J, Bernad A. Molecular characterization of spontaneous mesenchymal stem cell transformation. *PLoS ONE* 2008;3:e1398.
223. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A. Spontaneous human adult stem cell transformation. *Cancer Research* 2005;65:3035-3039.

224. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science* 2002;295:2097-2100.
225. Ruiter DJ, Ferrier CM, van Muijen GNP, Henzen-Logmans SC, Kennedy S, Kramer MD, Nielsen BS, Schmitt M. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. *Eur J Cancer* 1998;34:1334-1340.
226. Saarikoski ST, Rivera SP, Hankinson O, Husgafvel-Pursiainen K. CYP2S1: a short review. *Toxicol Appl Pharmacol* 2005;207:62-69.
227. Saeter G, Elomaa I, Wahlqvist Y, Alvegard TA, Wiebe T, Monge O, Forrestier E, Solheim OP. Prognostic factors in bone sarcomas. *Acta Orthopaedica Scandinavica* 1997;68:156-160.
228. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic Relapse of Patients with Osteogenic-Sarcoma. *Cancer* 1995;75:1084-1093.
229. Salas S, Jezequel P, Campion L, Deville JL, Chibon F, Bartoli C, Gentet JC, Charbonnel C, Gouraud W, Voutsinos-Porche B, Brouchet A, Duffaud F, Figarella-Branger D, Bouvier C. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2. *Int J Cancer* 2009;125:851-860.
230. Sandberg AA, Bridge JA. Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors. *Cancer Genet Cytogenet* 2000;123:1-26.
231. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. *Cancer Genetics and Cytogenetics* 2003;145:1-30.
232. Schwartz V, Lue HQ, Kraemer S, Korbil J, Krohn R, Ohl K, Bucala R, Weber C, Bernhagen J. A functional heteromeric MIF receptor formed by CD74 and CXCR4. *Febs Letters* 2009;583:2749-2757.
233. Scielzo C, Chia P, Conti A, Bachi A, Guida G, Geuna M, Alessio M, Caligaris-Cappio F. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. *J Clin Invest* 2005;115:1644-1650.
234. Screpanti V, Wallin RPA, Ljunggren HG, Grandien A. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. *J Immunol* 2001;167:2068-2073.
235. Serra M, Reverter-Branch, Maurici D, Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M, Scotlandi K, Picci P. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. *Ann Oncol* 2004;15:151-160.
236. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, Degiovanni C, Toffoli G, Baldini N. Establishment and Characterization of Multidrug-Resistant Human Osteosarcoma Cell-Lines. *Anticancer Res* 1993;13:323-329.
237. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. Macrophage polarization in tumour progression. *Seminars in Cancer Biology* 2008;18:349-355.
238. Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van DJ, Mantovani A. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. *J Immunol* 2000;164:762-767.
239. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. *Journal of Immunology* 2005;174:636-645.
240. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol* 2004;3:Article3.
241. Sorensen AL, Rumjantseva V, Nayeb-Hashemi S, Clausen H, Hartwig JH, Wandall HH, Hoffmeister KM. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. *Blood* 2009;114:1645-1654.
242. Sottnik JL, U'ren LW, Thamm DH, Withrow SJ, Dow SW. Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. *Cancer Immunol Immunother* 2010;59:367-378.
243. Souhami RL, Craft AW, VanderEijken JW, Nooij M, Spooner D, Bramwell VHC, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, VanGlabbeke M, Machin D. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. *Lancet* 1997;350:911-917.
244. Spierings E, Wieles B, Goulmy E. Minor histocompatibility antigens big in tumour therapy. *Trends in Immunology* 2004;25:56-60.

245. Spilsbury K, Omara MA, Wu WM, Rowe PB, Symonds G, Takayama Y. Isolation of A Novel Macrophage-Specific Gene by Differential Cdna Analysis. *Blood* 1995;85:1620-1629.
246. Starnes CO. Coley's toxins in perspective. *Nature* 1992;357:11-12.
247. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell* 2011;144:27-40.
248. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System Project. *European Journal of Cancer* 2006;42:2124-2135.
249. Strander H. Interferons and osteosarcoma. *Cytokine & Growth Factor Reviews* 2007;18:373-380.
250. Su KH, Yang HX, Li XR, Li XL, Gibson AW, Cafardi JM, Zhou T, Edberg JC, Kimberly RP. Expression profile of Fc gamma R1B on leucocytes and its dysregulation in systemic lupus erythematosus. *Journal of Immunology* 2007;178:3272-3280.
251. Suzhai K, Cleton-Jansen AM, Hogendoorn PCW, Bovee JV. Molecular pathology and its diagnostic use in bone tumors. *Cancer Genet* 2012;205:193-204.
252. Suzhai K, Ijszenga M, Tanke HJ, Rosenberg C, Hogendoorn PCW. Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines. *Cancer Genet Cytogenet* 2006;166:173-179.
253. Suzhai K, Tanke HJ. COBRA: combined binary ratio labeling of nucleic acid probes for multi-color fluorescence in situ hybridization karyotyping. *Nature Protocols* 2006;1:264-275.
254. Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M, Dulong J, Monnier D, Gourmelon P, Gorin NC, Sensebe L. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. *Blood* 2010;115:1549-1553.
255. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. *Nat Immunol* 2008;9:486-494.
256. Thompson RC, Cheng EY, Clohisy DR, Perentesis J, Manivel C, Le CT. Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery. *Clinical Orthopaedics and Related Research* 2002;240-247.
257. Tian Y, Jain S, Kelemen SE, Autieri MV. AIF-1 expression regulates endothelial cell activation, signal transduction, and vasculogenesis. *American Journal of Physiology-Cell Physiology* 2009;296:C256-C266.
258. Tian Y, Kelemen SE, Autieri MV. Inhibition of AIF-1 expression by constitutive siRNA expression reduces macrophage migration, proliferation, and signal transduction initiated by atherogenic stimuli. *American Journal of Physiology-Cell Physiology* 2006;290:C1083-C1091.
259. Tolar J, Nauta AJ, Osborn MJ, Mortari AP, McElmurry RT, Bell S, Xia LL, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, Mcivor RS, Hogendoorn PCW, Suzhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR. Sarcoma derived from cultured mesenchymal stem cells. *Stem Cells* 2007;25:371-379.
260. Torsvik A, Rosland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lonning PE, Primon M, Sobala E, Tonn JC, Goldbrunner R, Schichor C, Mysliwicz J, Lah TT, Motaln H, Knappskog S, Bjerkvig R. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. *Cancer Res* 2010;70:6393-6396.
261. Tronc F, Conter C, Marec-Berard P, Bossard N, Remontet L, Orsini A, Gamondes JP, Louis D. Prognostic factors and long-term results of pulmonary metastasectomy for pediatric histologies. *Eur J Cardiothorac Surg* 2008;34:1240-1246.
262. Tsukahara T, Kawaguchi S, Toriogoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. *Cancer Science* 2006;97:1374-1380.
263. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proceedings of the National Academy of Sciences of the United States of America* 2001;98:5116-5121.
264. Uccelli A, Prockop DJ. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? *Curr Opin Immunol* 2010;22:768-774.

1

2

3

4

5

6

7

8

&

265. Uehara H, Shacter E. Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for met tyrosine kinase-mediated phagocytosis of apoptotic cells. *Journal of Immunology* 2008;180:2522-2530.
266. van Dongen M., Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH, Hogendoorn PCW, van der Burg SH, Gelderblom H, van HT. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. *Int J Cancer* 2010;127:899-909.
267. Van Ginderachter JA, Movahedi K, Van den BJ, De BP. Macrophages, PPARs, and Cancer. *PPAR Res* 2008;2008:169414.
268. van Ostaïjen-ten Dam M, Verhoeven D, Kraal K, Bongaerts R, van Bergen J, Ball LM, Lankester A, van Tol M, Zwaginga J. Preclinical validation of an NK cell preparation: phenotype and function of NK cell products isolated via CliniMacs and subsequent ex vivo activation with IL-2 or IL-15. *Bone Marrow Transplantation* 2010;45:S302-S303.
269. Van Rijk-Zwikker GL, Nooy MA, Taminiu A, Kappetein AP, Huysmans HA. Pulmonary Metastasectomy in Patients with Osteosarcoma. *European Journal of Cardio-Thoracic Surgery* 1991;5:406-409.
270. Velardi A, Ruggeri L, Mancusi A. Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. *Curr Opin Hematol* 2012;19:319-323.
271. Venge P, Bystrom J. Eosinophil cationic protein (ECP). *Int J Biochem Cell Biol* 1998;30:433-437.
272. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PCW, Egeler RM, van Tol MJ, Schilham MW, Lankester AC. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. *Mol Immunol* 2008;45:3917-3925.
273. Volodko N, Reiner A, Rudas M, Jakesz R. Tumour-associated macrophages in breast cancer and their prognostic correlations. *Breast* 1998;7:99-105.
274. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. *Osteoarthritis Cartilage* 2002;10:199-206.
275. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. *Oncogene* 2008;27:5932-5943.
276. Wang LL, Gannavarapu A, Kozinetz CA, Levy ML, Lewis RA, Chintagumpala MM, Ruiz-Maldonado R, Contreras-Ruiz J, Cunniff C, Erickson RP, Lev D, Rogers M, Zackai EH, Plon SE. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. *J Natl Cancer Inst* 2003;95:669-674.
277. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, Eilber FR, Eckardt JJ. Pulmonary Metastases of Stage IIB Extremity Osteosarcoma and Subsequent Pulmonary Metastases. *Journal of Clinical Oncology* 1994;12:1849-1858.
278. Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M. The role of interferons in the treatment of osteosarcoma. *Pediatr Blood Cancer* 2010;54:350-354.
279. White CD, Brown MD, Sacks DB. IQGAPs in cancer: A family of scaffold proteins underlying tumorigenesis. *Febs Letters* 2009;583:1817-1824.
280. Wiklund TA, Blomqvist CP, Raty J, Elomaa I, Rissanen P, Miettinen M. Postirradiation sarcoma. Analysis of a nationwide cancer registry material. *Cancer* 1991;68:524-531.
281. Wunder JS, Gokgoz N, Parkes R, Bull SB, Eskandarian S, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Malkin D, Mangham DC, Rock MJ, Bell RS, Andrulis IL. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. *J Clin Oncol* 2005;23:1483-1490.
282. Yamamoto A, Miyazaki T, Kadono Y, Takayanagi H, Miura T, Nishina H, Katada T, Wakabayashi K, Oda H, Nakamura K, Tanaka S. Possible involvement of I kappa B kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappa B ligand. *Journal of Bone and Mineral Research* 2002;17:612-621.
283. Yang SY, Chen W, Stashenko P, Li YP. Specificity of RGS10A as a key component in the RANKL signaling mechanism for osteoclast differentiation. *Journal of Cell Science* 2007;120:3362-3371.
284. Yoshimi R, Yamaji S, Suzuki A, Mishima W, Okamura M, Obana T, Matsuda C, Miwa Y, Ohno S, Ishigatsubo Y. The gamma-parvin-integrin-linked kinase complex is critically involved in leukocyte-substrate interaction. *Journal of Immunology* 2006;176:3611-3624.
285. Zavalov AV, Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. *Biochemical Journal* 2005;391:51-57.
286. Zhou JH, Zhu T, Hu CX, Li HY, Chen G, Xu G, Wang SX, Zhou JF, Ma D. Comparative genomics and function analysis on B11 family. *Computational Biology and Chemistry* 2008;32:159-162.

287. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. *J Leukoc Biol* 2007;81:584-592.
288. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. *Nature Reviews Immunology* 2008;8:59-73.
289. Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. *Blood* 2010; 30:2286-94.

1

2

3

4

5

6

7

8

&

References

ABBREVIATIONS

ADM	adrenomedullin
ANOVA	analysis of variance
APC	allophycocyanin
AR	antigen retrieval
BSA	bovine serum albumin
CDDP	cis-diamminedichloroplatinum, cisplatin
CT	computed tomography
CXCL	C-X-C chemokine ligand
CXCR	C-X-C chemokine receptor
DAMP	damage-associated molecular pattern
DAPI	4',6-diamidino-2-phenylindole
DC	dendritic cell
DE	differentially expressed
DNA	deoxyribonucleic acid
DNAM-1	DNAX accessory molecule-1
DX	doxorubicin
E:T	effector:target
EEF1A1	eukaryotic translation elongation factor 1 alpha 1
EOI	European Osteosarcoma Intergroup
EURAMOS	European and American Osteosarcoma Study Group
FBS	fetal bovine serum
FC	flow cytometry
FCS	fetal calf serum
FFPE	formalin-fixed paraffin-embedded
FITC	fluorescein isothiocyanate
grB	granzyme B
HCLS-1	hematopoietic cell specific Lyn substrate 1
HLA	human leukocyte antigen
IF	immunofluorescent
IFN	interferon
IHC	immunohistochemistry
IL	interleukin
JAK	janus kinase
KIR	Killer Immunoglobulin-like Receptor
LIMMA	Linear Models for Microarray Data
mDC	myeloid dendritic cell
MDP	muramyl dipeptide
MFI	mean fluorescence intensity
MHC	major histocompatibility antigen

1

2

3

4

5

6

7

8

&

Abbreviations

MIC	major histocompatibility class I polypeptide-related sequence
MMP	matrix metalloproteinase
MRI	magnetic resonance imaging
MSC	mesenchymal stromal cell
MTP	muramyl tripeptide
MTX	methotrexate
NCR	natural cytotoxicity receptor
NK cell	natural killer cell
NKG2D	Natural Killer Group 2, member D
NOD	nucleotide-binding and oligomerization domain
OS	osteosarcoma
PAMP	pathogen associated molecular pattern
PBMC	peripheral blood mononuclear cell
PBS	phosphate buffered saline
PCR	polymerase chain reaction
PD	population doublings
pDC	plasmacytoid dendritic cell
PE	phycoerythrin
PerCP	peridinin chlorophyll protein
PFA	paraformaldehyde
PS	penicillin/streptomycin
PVR	poliovirus receptor
RNA	ribonucleic acid
RT	reverse transcriptase
SAM	Significance Analysis for Microarrays
STAT	signal transducer and activator of transcription
TAM	tumor associated macrophage
TGF- β	transforming growth factor- β
ULBP	UL-16 binding protein
VEGF	vascular endothelial growth factor
WHO	World Health Organisation

PUBLICATIONS

E.P. Buddingh, S.E.N. Ruslan, C.M.A. Reijnders, M.L. Kuijjer, H. Roelofs, P.C.W. Hogendoorn, R.M. Egeler, A.M. Cleton-Jansen, A.C. Lankester. Mesenchymal stromal cells derived from osteosarcoma patients do not transform during long-term culture. *Submitted*.

M.L. Kuijjer, B.E.W.M. van den Akker, R. Hilhorst, M. Mommersteeg, **E.P. Buddingh**, M. Serra, H. Bürger, P.C.W. Hogendoorn, A. M. Cleton-Jansen. Kinome and mRNA expression profiling of high-grade osteosarcoma identifies genomic instability, and reveals Akt as potential target for treatment. *Submitted*.

M.L. Kuijjer, H. Rydbeck, S.H. Kresse, **E.P. Buddingh**, A.B. Lid, H. Roelofs, H. Bürger, O. Myklebost, P.C.W. Hogendoorn, L.A. Meza-Zepeda, A.M. Cleton-Jansen. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. *Genes Chromosomes Cancer*. 2012 Jul;51(7):696-706.

E.P. Buddingh, S.E.N. Ruslan, D. Berghuis, H. Gelderblom, J.K. Anninga, P.C.W. Hogendoorn, R.M. Egeler, M.W. Schilham, A.C. Lankester. Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients. *Cancer Immunol Immunother*. 2012 Jun;61(6):941-7.

A.M. Cleton-Jansen, **E.P. Buddingh**, A.C. Lankester. Immunotherapy: Is it different for sarcomas? *Oncoimmunology*. 2012 Mar 1;1(2):255-257.

D. Berghuis, M.W. Schilham, H.I. Vos, S.J. Santos, S. Kloess, **E.P. Buddingh**, R.M. Egeler, P.C.W. Hogendoorn, A.C. Lankester. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytotoxicity. *Clin Sarcoma Res*. 2012 Feb 8;2(1):8.

J.H. Pahl JH, S.E.N. Ruslan, **E.P. Buddingh**, S.J. Santos, K. Szuhai, M. Serra, H. Gelderblom, P.C.W. Hogendoorn, R.M. Egeler, M.W. Schilham, A.C. Lankester. Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma. *Clin Cancer Res*. 2012 Jan 15;18(2):432-41.

E.P. Buddingh, M.W. Schilham, S.E.N. Ruslan, D. Berghuis, K. Szuhai, J. Suurmond, A.H.M. Taminiau, H. Gelderblom, R.M. Egeler, M. Serra, P.C.W. Hogendoorn, A.C. Lankester. Chemotherapy resistant osteosarcoma is highly susceptible to IL-15 activated allogeneic and autologous NK cells. *Cancer Immunol Immunother*. 2011 Apr;60(4):575-86.

E.P. Buddingh, M.L. Kuijjer, R. A.J. Duim, H. Bürger, K. Agelopoulos, O. Myklebost, M. Serra, F. Mertens, P.C.W. Hogendoorn, A.C. Lankester, A.M. Cleton-Jansen. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents. *Clin Cancer Res*. 2011 Apr 15;17(8):2110-9.

C.M.A. Reijnders, C.J.F. Waaijer, A. Hamilton, **E.P. Buddingh**, S. Dijkstra, J. Ham, E. Bakker, K. Szuhai, M. Karperien, P.C.W. Hogendoorn, S.E. Stringer, J.V.M.G. Bovée. No haploinsufficiency but two hits in EXT in osteochondroma formation. *Am J Pathol*. 2010 Oct;177(4):1946-57.

1

2

3

4

5

6

7

8

&

Publications

E.P. Buddingh, J.K. Anninga, M.I.M. Versteegh, A.H.M. Taminiu, R.M. Egeler, C.S.P. van Rijswijk, P.C.W. Hogendoorn, A.C. Lankester, H. Gelderblom. Prognostic Factors In Pulmonary Metastasized High-Grade Osteosarcoma. *Pediatr Blood Cancer*. 2010 Feb; 54(2):216-221.

A.B. Mohseny, K. Szuhai, S. Romeo, **E.P. Buddingh**, I. Briaire-de Bruijn, D. de Jong, M. van Pel, A.M. Cleton-Jansen, P.C.W. Hogendoorn. Homozygous Deletion of CDKN2 in Tumorigenic Mesenchymal Stem Cells: a Key Event for Osteosarcoma Genesis. *J Pathol*. 2009 Nov;219(3):294-305.

A. Taminiu, J. Anninga, H. Gelderblom, C. Rijswijk, P. Hogendoorn, **E. Buddingh**, S. Dijkstra. Chirurgische mogelijkheden bij osteosarcoom: onderdeel van een multidisciplinair probleem. *Oncollectie*. 2008 (3): 2-7.

E.P. Buddingh, A. van Hylckama Vlieg, F.R. Rosendaal. The Angiotensin-Converting Enzyme Gene insertion/deletion polymorphism: insufficient evidence for a role in deep venous thrombosis. *J Thromb Haemost*. 2005 Feb; 3 (2): 403-4.

E.P. Buddingh, S. Naumann, M. Nelson, J.R. Neff, N. Birch, J.A. Bridge. Cytogenetic findings in benign cartilaginous neoplasms. *Cancer Genetic Cytogenet*. 2003 Mar;141(2):164-8.

E.P. Buddingh, P. Krallman, J.R. Neff, M. Nelson, J. Liu, J.A. Bridge. Chromosome 6 abnormalities are recurrent in synovial chondromatosis. *Cancer Genet Cytogenet*. 2003 Jan;140(1):18-22.

CURRICULUM VITAE

Emilie Pauline (Emmeline) Buddingh'

25 juni 1979, Ede

1990-1997

Middelbare school

Voorbereidend Wetenschappelijk Onderwijs ('90-'96), Radulphus College, Curaçao
Curaçao-American Preparatory School ('96-'97), Curaçao

1997-2004

Geneeskunde, Universiteit Leiden

Artsexamen januari 2005, *Cum Laude*

1999-2004

Wetenschappelijke stages

Pathologie, Moleculaire Cel Biologie, Epidemiologie, LUMC, Leiden

Klinische genetica, VUMC, Amsterdam

Pathologie, University of Nebraska Medical Center, Nebraska, VS

2004

Keuze-coschappen

Klinische genetica, VUMC, Amsterdam

Tropengeneeskunde, Iogowe Hospital, Tukuyu, Tanzania

2005

Arts-assistent niet in opleiding

Kindergeneeskunde, Het LangeLand ziekenhuis, Zoetermeer

2006

Arts-assistent niet in opleiding

Kindergeneeskunde, Sophia Kinderziekenhuis, ErasmusMC, Rotterdam

2007 - 2010

Promotie-onderzoek (ZonMW AIOSKO-beurs)

Immunologisch Laboratorium Kindergeneeskunde

& afdeling Pathologie, LUMC, Leiden

Sinds 2010

Kinderarts in opleiding

Willem-Alexander Kinderziekenhuis, LUMC, Leiden

& Juliana Kinderziekenhuis, Hagaziekenhuis, Den Haag

1

2

3

4

5

6

7

8

&

Curriculum Vitae

DANKWOORD

In de aanloop van het project, gedurende de drie labjaren en in de afrondingsfase daarna ben ik door velen geholpen. Ik hoop dat ik gaandeweg mijn waardering al heb laten blijken, maar ik maak toch graag van de gelegenheid gebruik om een aantal mensen met nadruk te bedanken.

Dr. A.C. Lankester, co-promotor. Arjan, fundamenteel onderzoek en klinisch werk gaan bij jou hand in hand, dat is een mooi voorbeeld dat ik ooit hoop te kunnen volgen. Dank voor de vrijheid die je me gaf om zelf (mede) de richting van het onderzoek te bepalen en in de afronding mijn eigen tempo te kiezen. Prof. Dr. P.C.W. Hogendoorn, promotor. Pancras, onder jouw vleugels zette ik als tweedejaars geneeskundestudent de eerste schreden in onderzoeksland. Ik vind het erg leuk dat jij niet alleen aan het begin van mijn onderzoekservaring een sturende rol hebt gehad, maar dat ook in opzet, uitvoering en voltooiing van deze promotie hebt gehad. Prof. Dr. R.M. Egeler, promotor. Maarten, in alle fasen van dit onderzoek heb jij me steeds met positieve bijdragen ondersteund. Ook vanuit Toronto waren jouw commentaren op de laatste onderdelen van dit proefschrift steeds bemoedigend, dank voor deze steun in de rug tijdens de laatste loodjes.

Dr. Cleton-Jansen en Dr. Schilham: Anne-Marie en Marco, jullie hebben beiden ontzettend veel betekend voor dit proefschrift. Marco, je kritische blik hebben veel dingen aangescherpt en beter gemaakt. Ettelijke keren waaide ik onaangekondigd met een vraag je kamer in en kon jij weer een lacune in mijn immunologie-kennis dichtten, dank daarvoor. Anne-Marie, ik denk nog met veel plezier terug aan die keer dat jij letterlijk springend naast de microscoop stond toen we een binucleaire MSC hadden ontdekt. Dank voor je enthousiasme en positivisme.

Mijn lieve maatjes in het lab, Dagmar Berghuis en Willemijn Quispel, dank voor alle gezelligheid en steun, toen en nu! Wat fijn dat jullie mijn paranimfen willen zijn. Dagmar, niemand anders weet zó goed hoe het is een proefschrift over sarcoom-immunologie te verdedigen, het is een geruststellend idee dat jij tijdens de verdediging naast mij staat. Willemijn, jouw kritische blik en overdosis empathie waardeerde ik eerst als collega, waardeer ik nu als vriendin en maakt van jou straks ongetwijfeld een geweldige arts.

Alle lab-collega's van de kindergeneeskunde en de pathologie, bedankt voor de gezelligheid, collegialiteit en waar nodig praktische hulp. Riri, you are a very fun person to be around and I am honoured and grateful that you were the technician on this project. Susy, mede dankzij je Zuid-Amerikaanse roots en je warme karakter heb ik me snel thuis gevoeld op het lab, muito obrigada! Mijn studenten Bas, Kimberly, Sharon, Joyce, Milou en Jolien: hoewel niet al jullie bijdragen de weg naar dit proefschrift gevonden hebben, heb ik van elk van jullie wat geleerd, dank daarvoor en dank voor jullie inzet. Alle mede-aio's en P3-35 kamerogenoten: dank voor de samenwerking en de fijne tijd. Alle huidige en voormalige collega's van de kindergeneeskunde in Leiden en Den Haag, dank voor de interesse en de bemoedigende woorden tijdens de afrondingsfase.

Speciale dank gaat uit naar de patiënten en hun ouders. Juist op het moment van het krijgen van een verpletterende diagnose waren er zovelen die onbaatzuchtig 'ja' zeiden op de vraag of ze mee wilden doen aan wetenschappelijk onderzoek. Zonder deze bijdrage waren de meeste onderdelen van dit proefschrift niet mogelijk geweest. Ook dank ik iedereen die heeft geholpen

1

2

3

4

5

6

7

8

&

Dankwoord

met het verkrijgen van informed consent en het verzamelen en verwerken van de biologische materialen, in het bijzonder Professor Hans Gelderblom, Professor Antonie Taminiau, Sander Dijkstra, Nicolette Leyerzapf, Karoly Szuhai, Daniëlle de Jong en Jakob Anninga.

Familie en vrienden, hier of op een zeker tropisch eiland, dank voor de broodnodige ontspanning naast het werk. Dank voor alle leuke weekenden, etentjes, vakanties, borrels en BBQs. Met name Juliëtte, Donnée, Liesbeth, Sandra en Marlies: dank!

Lieve ouders, goed voorbeeld doet goed volgen: jullie plezier en vasthoudendheid in het doen van onderzoek en het schrijven van boeken is inspirerend. Dit, en jullie onvoorwaardelijke steun, heeft zeker bijgedragen aan het voltooien van dit proefschrift.

Lieve Maarten, dank voor alles! Als arts zijn er grote hiaten in mijn moleculair biologische kennis, die jij onvermoeibaar opvult. Maar bovenal duizendmaal dank voor je steun en liefde, in voorspoedige en minder voorspoedige tijden. Wat bof ik.